Upstream Bio, Inc. Common Stock
UPBStock
$7.23−39.13%52W
Market Cap$388.56M
P/E—
Div yield—
Beta1.70
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-81.08%
Price vs S&P 500 (4W)17.45%
VGM Score42.38
Market Capitalization$388.56M
Earnings Surprise History
Q1 26-0.75est. -0.78
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.00
4.00
4.00
3.92
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
UPBUpstream Bio, Inc. Common Stock | D | B | F | $7.23 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Upstream Bio is a clinical-stage biotechnology company developing verekitug, a TSLP receptor antagonist for inflammatory diseases. The company is initially targeting severe respiratory disorders where TSLP is a validated pathological driver. This upstream target addresses multiple immune-mediated disease indications.